287 related articles for article (PubMed ID: 25048046)
1. Going further in the knowledge of Yondelis®; what's new in clinical trials?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
[TBL] [Abstract][Full Text] [Related]
2. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin's contribution to the treatment of sarcomas.
Blay JY
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
[TBL] [Abstract][Full Text] [Related]
4. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
5. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
9. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
10. Current questions in soft tissue sarcoma: further steps with Yondelis®.
Reichardt P
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):25-30. PubMed ID: 23638728
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
15. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
19. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE
J BUON; 2010; 15(4):791-3. PubMed ID: 21229647
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
